[Prophylaxis of respiratory syncytial virus infections with palivizumab].
Danés Carreras
I
I
Arnau De Bolós
J M
JM
D000367:Age Factors; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D006760:Hospitalization; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D015337:Multicenter Studies as Topic; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab
Profilaxis de las infecciones por el virus respiratorio sincitial con palivizumab.